☆ 4.6 Editorial Material

Resolving the tissue response to neoadjuvant chemotherapy in rectal cancer

CELL REPORTS MEDICINE (2023)

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Preoperative Treatment of Locally Advanced Rectal Cancer

Deborah Schrag et al.

Summary: Preoperative FOLFOX chemotherapy is as effective as preoperative chemoradiotherapy for locally advanced rectal cancer eligible for sphincter-sparing surgery.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection
Review Immunology

Single-cell sequencing technology in colorectal cancer: a new technology to disclose the tumor heterogeneity and target precise treatment

Rongbo Wen et al.

Summary: Colorectal Cancer (CRC) is a common gastrointestinal tumor with high heterogeneity. Traditional sequencing methods cannot capture the heterogeneity of individual cancer cells. Single-cell sequencing technology can analyze the genetic and protein differences between cells, providing a more comprehensive understanding of colorectal cancer development and metastasis. This study reviews the application of single-cell sequencing in analyzing the tumor microenvironment of CRC and exploring the mechanisms involved in metastasis and progression, providing a reference for potential treatment options.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection
Article Cell Biology

Cancer-associated fibroblasts undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell and spatial transcriptomics

Pengfei Qin et al.

Summary: Our study uses single-cell RNA sequencing and spatial transcriptome sequencing to examine the cell dynamics in RC patients before and after treatment. We find that NAC remodels the populations of cancer-associated fibroblasts, leading to improved therapeutic response and inhibition of tumor progression through modulation of the tumor microenvironment.

CELL REPORTS MEDICINE (2023)

Add to Collection
Meeting Abstract Gastroenterology & Hepatology

Preoperative Treatment of Locally Advanced Rectal Cancer

D. Schrag et al.

DISEASES OF THE COLON & RECTUM (2023)

Add to Collection
Article Medicine, General & Internal

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer

Andrea Cercek et al.

Summary: This study found that mismatch repair-deficient, locally advanced rectal cancer is highly sensitive to PD-1 blockade. Additionally, no adverse events of grade 3 or higher have been reported, and no cases of progression or recurrence have been observed. Longer follow-up is needed to assess the duration of response.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Oncology

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer et al.

Summary: The RAPIDO trial aimed to reduce systemic relapses in locally advanced rectal cancer through short-course radiotherapy, chemotherapy, and delayed surgery. Results showed a decreased probability of disease-related treatment failure in the experimental group compared to standard care, with diarrhea being the most common adverse event and neurological toxicity being prominent in the standard care group during adjuvant chemotherapy.

LANCET ONCOLOGY (2021)

Add to Collection
Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection
Article Oncology

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy et al.

Summary: In patients with cT3 or cT4 M0 rectal cancer, intensifying chemotherapy with FOLFIRINOX before preoperative chemoradiotherapy significantly improved disease-free survival outcomes and reduced neurotoxicity. Thus, the PRODIGE 23 results have the potential to impact clinical practice.

LANCET ONCOLOGY (2021)

Add to Collection
Article Oncology

Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial

Yanhong Deng et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection
Article Genetics & Heredity

Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

Alexandre Calon et al.

NATURE GENETICS (2015)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.